(Q45876857)

17 December 2017

title

Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects (English)

1 reference

17 December 2017

main subject

hemophilia

0 references

Coagulation factor VIII

0 references

0 references

1 reference

J Batlle

1

1 reference

17 December 2017

E Gómez

2

1 reference

17 December 2017

E Rendal

3

1 reference

17 December 2017

J Torea

4

1 reference

17 December 2017

E Lourés

5

1 reference

17 December 2017

M Couselo

6

1 reference

17 December 2017

P Vila

7

1 reference

17 December 2017

C Sedano

8

1 reference

17 December 2017

X Tusell

9

1 reference

17 December 2017

M Magallón

10

1 reference

17 December 2017

M Quintana

11

1 reference

17 December 2017

R González-Boullosa

12

1 reference

17 December 2017

M F López-Fernández

13

1 reference

17 December 2017

publication date

1 May 1996

1 reference

17 December 2017

published in

Annals of Hematology

1 reference

17 December 2017

volume

72

1 reference

17 December 2017

issue

5

1 reference

17 December 2017

page(s)

321-326

1 reference

17 December 2017

Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Anti-idiotypic suppression of antibodies to factor VIIIc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Why do so many haemophilia A patients develop an inhibitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Complications of hemophilia A treatment: factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Anti-idiotypes to factor VIII antibodies and their possible role in the pathogenesis and treatment of factor VIII inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Disappearance of inhibitor to factor VIII in HIV-infected hemophiliacs with progression to AIDS or severe ARC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Factor VIII structure and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS002770050179

Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction.

21 January 2018

1 reference

12 December 2020

The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors

1 reference

12 December 2020

FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting

1 reference

12 December 2020

Induced immunotolerance in factor VIII inhibitor patients.

1 reference

12 December 2020

Noncoagulation inhibitory factor VIII antibodies after induction of tolerance to factor VIII in hemophilia A patients

1 reference

12 December 2020

The idiotypic characteristics of human antibodies to factor VIII

1 reference

12 December 2020

Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg)

1 reference

12 December 2020

Autoimmune factor VIII inhibitor responsive to gammaglobulin without in vitro neutralisation

1 reference

12 December 2020

Impact of replacement therapy on the evolution of HIV infection in hemophiliacs

1 reference

12 December 2020

Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report

1 reference

12 December 2020

Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time

1 reference

12 December 2020

Identifiers

DOI

10.1007/S002770050179

1 reference

17 December 2017

1 reference

17 December 2017